Trade Summary

3 days ago, Smith Mark Douglas, serving as Dir at Jazz Pharmaceuticals plc (JAZZ), sold 1,157 shares at $230.55 per share, for a total transaction value of $266,746.35. Following this transaction, Smith Mark Douglas now holds 9,680 shares of JAZZ.

This sale represents a 10.68% decrease in Smith Mark Douglas's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 15, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, June 17, 2026 at 4:45 PM ET, 2 days after the trade was made.

Jazz Pharmaceuticals plc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.